Icon inks Proteome deal to bolster biomarker offering
This content item was originally published on www.biopharma-reporter.com, a William Reed online publication.
Icon is adding protein and peptide profiling to its biomarker capabilities through a strategic alliance with Proteome Sciences.
Over the past 10 years Icon has built up its biomarker capabilities as it works to help clients make more informed drug development decisions. Building on this progress Icon has inked a deal with Proteome.
At AAPS 2010 Outsourcing-Pharma discussed the deal with Brian O'Dwyer, vice president (VP) of bioanalytical development, and John Allinson, VP biomarker lab services.
In a press statement Ian Pike, chief operating officer at Proteome, said the deal is recognition of the ‘unique power’ of its proprietary technology platforms.
